[Surveillance on antibiotic resistance of Stenotrophomonas maltophilia in Chengdu and Chongqing area].
OBJECTIVE
To survey the antibiotic resistance of Stenotrophomonas maltophilia in Chengdu and Chongqing area and guide the rational antibiotics usage in the treatment of Stenotrophomonas maltophilia infection.


METHODS
Minimal inhibitory concentrations (MICs) of 9 antibiotics against Stenotrophomonas maltophilia were measured using two-fold agar dilution method.


RESULTS
A total of 154 strains of Stenotrophomonas maltophilia are multi-drug resistant. But the resistant ratios of trimethoprim-sulfamethoxazole, ticarcillin-clavavulanic acid and fluoroquinolones are lower; especially, new fluoroquinolones have stronger antimicrobial activities.


CONCLUSIONS
The rate of isolating Stenotrophomonas maltophilia strains from clinical samples has been rising. In the therapy of Stenotrophomonas maltophilia infection, trimethoprim-sulfamethoxazole or fluoroquinolones is empirically the medicine of choice. For the treatment of serious infection, the administration of trimethoprim-sulfamethoxazole combined with ticarcillin-clavavulanic acid or new fluoroquinolones is rational.
Division of Clinical Microbiology, Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Chuan-min
CM
Tao
Xiao-chun
XC
Li
Xiao-ju
XJ
Lü
Ping
P
Li
Ru-jia
RJ
Yu
Yan-yu
YY
Gao
Hui-li
HL
Chen
D000890:Anti-Infective Agents / Q000494:pharmacology*; D019818:Clavulanic Acid / Q000494:pharmacology; D024901:Drug Resistance, Multiple, Bacterial; D024841:Fluoroquinolones / Q000494:pharmacology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D020615:Stenotrophomonas maltophilia / Q000187:drug effects*; D013982:Ticarcillin / Q000494:pharmacology*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000494:pharmacology*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D019818:Clavulanic Acid; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D013982:Ticarcillin